Five Prime Therapeutics, Inc. reported earnings results for first quarter ended March 31, 2018. For the period, the company's collaboration and license revenue was $32,486,000 against $10,135,000 a year ago. Operating loss was $21,544,000 against $34,111,000 a year ago. Loss before income tax was $20,390,000 against $33,443,000 a year ago. Net loss was $20,390,000 against $33,443,000 a year ago. Basic and diluted net loss per common share was $0.63 against $1.21 a year ago.

The company expects full-year 2018 net cash used in operating activities to be less than $135 million, which includes the previously mentioned milestone payments earned by Five Prime. Five Prime estimates ending 2018 with approximately $250 million in cash, cash equivalents and marketable securities.